期刊
NPJ VACCINES
卷 2, 期 -, 页码 -出版社
NATURE PORTFOLIO
DOI: 10.1038/s41541-017-0011-y
关键词
-
资金
- Johns Hopkins Malaria Research Institute
- Bloomberg Family Foundation
- National Institutes of Health/NIAID grant [AI44375]
Despite several decades of extensive research, the development of a highly efficacious malaria vaccine has yet to be accomplished. While the RTS,S malaria vaccine candidate shows the potential to prevent a substantial number of clinical malaria cases, significant improvements in protective efficacy are still needed. Multiple studies have shown that RTS, S induces protective antibody and CD4(+) T-cell responses, but limited or negligible CD8(+) T cells. In this study, we evaluated the immunogenicity and protective capacity of full-length recombinant Plasmodium falciparum circumsporozoite protein administered with the novel cationic liposomal adjuvant system CAF09. Using newly developed transgenic rodent malaria parasites expressing the full-length Plasmodium falciparum circumsporozoite protein, we demonstrate that this liposome-based protein-in-adjuvant formulation is capable of inducing robust antibody and CD8(+) T-cell responses that strongly inhibit parasite infection and development of liver stages, conferring durable sterilizing immunity. These findings underscore the potential of liposome-based adjuvants for inducing robust humoral and CD8(+) T-cell responses and warrant further studies toward the development of novel subunit vaccine formulations with this adjuvant system.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据